Brooks Lab. (BROOKS)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Brooks Lab is a classic example of why a low P/E can be an illusion. At ₹64.77, the market cap is ₹198 Cr, and the trailing P/E of 9.15 looks cheap. But Graham taught us to look beneath the surface. Sales are down 19.25%, and while profit growth of 358.22% sounds impressive, it likely stems from a weak base, not durable earnings. The latest quarter shows sales of ₹17 Cr and net profit of ₹6 Cr — a 35% margin, which is extraordinary for a pharma company. I'd ask: is that sustainable, or is it an aberration? ROCE is negative at -9.93%, meaning the company isn't generating a return on capital employed. That's a red flag for any business claiming operational health. ROE is 9.34%, but with negative ROCE, the equity return may be inflated by financial engineering or one-off gains. The balance sheet is clean — debt/equity of 0.07 — and promoter holding is a solid 52.62%. But zero dividend yield tells me shareholders aren't being paid to wait. The book value is ₹24.11, so P/B of 2.69 means I'm paying a premium for assets that aren't earning well. The 52-week range of ₹36.30 to ₹164.02 shows the stock was once a high flyer and has crashed. Is this a fallen gem or a value trap? At F-Score 5/9, fundamentals are mediocre. I'd need to see sales stabilize and ROCE turn positive before I commit. This smells like a potential turnaround, but the evidence is still incomplete. I'll wait for more data.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer